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terchangeable 300 and 400 mg dose. RESULTS: Model
data captured 99% of all feasible 2:1 interchanges. Cost
savings predicted form administrative data varied be-
tween 82 and 150 percent of actual savings using the pre-
scription direction model. CONCLUSIONS: Administra-
tive pharmacy data is a poor predictor of cost savings for
2:1 interchange protocols for medications with highly
variable dosing regimens such as gabapentin. A model
utilizing prescription directions may be beneficial in for-
mulary decision-making where highly accurate estimates
are necessary.
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OBJECTIVE: The Disability in Strategies for Care (DISC)
study compared, in 835 patients, a stratified care strat-
egy, where initial therapy for migraine is based on clini-
cal need, and two stepped care strategies (across attacks
and within attacks), where first-line therapy with simple
analgesic is escalated, if response has been inadequate, to
zolmitriptan—a migraine-specific therapy. We report on
a stochastic cost-effectiveness analysis (CEA) of these
three strategies. METHODS: The analysis adopted a so-
cietal perspective, including health service and productiv-
ity costs (1998–1999 prices). Data were collected on drug
usage (main therapy, rescue and adverse event manage-
ment); other resource use associated with adverse events
was estimated by a clinician blinded to treatment strat-
egy. Productivity costs were based on diary card data for
time patients lost from work, and on reduced effective-
ness at work. CEA related differential cost to the trial’s
two primary outcome measures: headache response at
two hours and disability-adjusted time over 4 hours. RE-
SULTS: Total mean cost over six attacks was lowest in
the stratified group (£138.95; 95% CI 122.38, 158.93)
compared to £157.19 (95% CI 134.50, 184.93) in the
stepped across attacks group and £148.53 (95% CI
123.04, 179.41) in the stepped care within attacks group.
Both measures of effectiveness showed an improvement
in the stratified arm. In terms of mean costs and effects,
stratified care represents a dominant strategy. Cost-effec-
tiveness acceptability curves indicate that, depending on
the value that decision-makers place on a unit of out-
come, the probability that stratified care is the most cost-
effective strategy ranges from 58% to 100% for the 2-
hour response rate and from 62% to 98% for disability-
adjusted time. CONCLUSION: Given its lower mean
costs and higher mean effectiveness, stratified care, which
included zolmitriptan, is the dominant strategy. When
uncertainty is considered, stratified care has the highest
probability of being cost-effective.
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OBJECTIVE: Estimate the long–term health and economic
impact in Sweden of treating patients with mild to moderate
Alzheimer’s disease (AD) with galantamine. METHODS:
The estimates are derived from an economic model con-
sisting of two parts. The short–term component was based
on the galantamine clinical trials. The long-term compo-
nent predicted, on the basis of trial results and equations
derived from recently published data, when patients
would require full time care (FTC) or die. Resources used
before FTC and for FTC were estimated from the litera-
ture, using an overall health care payer perspective. RE-
SULTS: Approximately 5.6 patients must start treatment
to avoid one year of FTC. Overall net savings of galan-
tamine compared to no treatment ranged from SEK
27,500 (all subjects) to SEK 59,000 (moderate patients
only). Univariate and multivariate sensitivity analyses of
key parameters, such as the cost of galantamine, cost of
FTC not in a nursing home (NH), cost of FTC in NH and
proportion of FTC patients in NH, supported the robust-
ness of these findings. For instance, a multivariate sensi-
tivity analysis found that if the cost of FTC outside a NH
is 50% of NH costs, instead of the 71% reported in the
literature, and only 50% of patients requiring FTC reside
in NH instead of the reported 85%, the net savings are
SEK 10,400. CONCLUSION: Galantamine therapy de-
lays the need for FTC without leading to additional cost
in the treatment of mild to moderate AD in Sweden.
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OBJECTIVES: Epilepsy and its treatment can have pro-
found effects on the quality of life (QOL) of many pa-
tients, particularly those with seizures refractory to treat-
ment. Detecting changes in QOL in trials of anti-epileptic
drugs as add-on therapy over a short period is, however,
known to be difficult. METHODS: In this study, we ex-
amined the relationship between patients’ perception of
quality of life change, using QOL transition scales, and
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objective quality of life mean change scale scores, using
the QOLIE-31, for similar constructs in a 3-month study
of add-on therapy in 329 refractory epilepsy patients ex-
periencing partial seizures. The validity and responsive-
ness of the QOL transition scales, the QOLIE-31 scales,
compliance and treatment satisfaction scales were also
examined. RESULTS: Correlations between the QOL
transition scales and QOLIE-31, satisfaction and compli-
ance mean change scores were significant but low to
moderate (0.10–0.39) for the majority of scales. The QO-
LIE-31 worry scale and the treatment satisfaction scale
proved to be the most responsive to clinical changes. The
transition scales, however, often indicated that respond-
ers perceived significantly more improvement than non-
responders, particularly for change in social life and glo-
bal QOL. CONCLUSIONS: These results suggest that
measuring patients’ perception of change in QOL is not
the same as measuring change in QOL objectively (i.e.
over time). Perceptions appear to play an important role
in patients’ satisfaction with and willingness to continue
treatment. In addition, patients’ perceptions of treatment
and its effect on their lives appear sensitive to short-term
treatment. These changes may, however, be distinct from
those QOL domains that change with sustained control
of seizures. Further research into patient satisfaction and
perceptions of QOL change, particularly in short-term
epilepsy trials, may be valuable in refining measurement
methodology.
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OBJECTIVE: Clinical studies show that entacapone sig-
nificantly increases ON time. Increases in ON time are
associated with decreases in resource utilization. This
study is designed to examine the cost-effectiveness of
usual care with entacapone versus usual care without en-
tacapone in patients with Parkinson’s disease. The setting
for this study was The Netherlands. METHODS: A
Markov process model was constructed to model the av-
erage quality adjusted life years (QALYs) and the costs of
both treatments. The 5-year model captured the impact
of treatment on symptoms and disease progression. Data
for the construction of the model were derived from pub-
lished literature, including large multicenter randomized
clinical trials in patients with end-of-dose wearing off.
Costs were obtained primarily from published sources.
RESULTS: The results of the baseline analysis showed a
slight decrease of the 5-year total average discounted
costs from NLG 111,317 to NLG 110,038, resulting in
an effectiveness increase in the entacapone arm from 2.42
to 2.56 quality-adjusted life years (QALYs), a 6% in-
crease. In addition, entacapone substantially increased
“time in which patients are able to perform everyday ac-
tivities” by 0.63 years. Sensitivity analyses confirmed the
robustness of these findings. CONCLUSION: Entaca-
pone is a cost-effective treatment, yielding improvement
in terms of both effectiveness measures (time without se-
vere fluctuations and QALYs), without additional cost
when compared to PD treatment w/o entacapone. The
additional drug costs for entacapone are offset by reduc-
tions in other costs, especially hospitalization. 
PNR8
A CANADIAN ADAPTATION OF A DECISION 
ANALYTIC MODEL FOR THE ECONOMIC 
EVALUATION OF OPIOIDS FOR CHRONIC PAIN
Neighbors DM1, Lopez R1, Ingham M2, Bell TJ1
1Research Triangle Institute, Research Triangle Park, NC, USA; 
2Janssen Ortho, Inc., Toronto, ON, Canada
OBJECTIVES: To adapt a previously published US-based
model for economic evaluation of the fentanyl transder-
mal system and controlled-release oral morphine, for the
control of moderate to severe chronic pain, for use in
Canada. METHODS: A panel of Canadian experts con-
firmed the model’s clinical validity and provided esti-
mates of medical resource utilization to treat various
model events. We applied Canadian unit costs to these
estimates. We populated the model with the results from
a randomized cross-over trial of the fentanyl transdermal
system compared to oral morphine in patients with
chronic moderate to severe nonmalignant pain. We used
the adapted model to assess the incremental cost-utility
of the fentanyl transdermal system compared to con-
trolled-release morphine in Canadian patients with chronic
nonmalignant pain. RESULTS: The results of the Cana-
dian and US analyses were similar. Because Canada and
the US use different medical resources used to treat
events, the average total costs to treat opioid use-related
events decreased and were distributed differently. The
newly available event rates were similar to those used in
the U.S. model, which were pulled from disparate data
sources or estimated by clinical experts. In the Canadian
model, the incremental cost-utility ratio of the fentanyl
transdermal system compared to controlled-release oral
morphine is CAN$17,354 (compared to US$20,709). The
primary cost drivers are the cost of the opioid medica-
tions themselves, the use of rescue pain medication, and
the rate of discontinuation from the initial opioid ther-
apy. CONCLUSIONS: The incremental cost-utility of the
fentanyl transdermal system compared to controlled-re-
lease oral morphine does not change substantially when
evaluated using Canadian parameter estimates.
